| Side effect | Estradiol undecylate 100 mg/month i.m. (n = 96) |
Cyproterone acetate 100 mg/day oral (n = 95) | ||
|---|---|---|---|---|
| n | % | n | % | |
| Gynecomastia* | 74 | 77.1% | 12 | 12.6% |
| Breast tenderness* | 84 | 87.5% | 6 | 6.3% |
| Sexual impotence | "Occurred in essentially all patients of both groups"
| |||
| Leg edema* | 17 | 17.7% | 4 | 4.2% |
| Thrombosis | 4 | 4.2% | 5 | 5.3% |
| Cardiovascular mortality | 2 | 2.1% | 2 | 2.1% |
| Other mortality | 1a | 1.0% | 0 | 0% |
| Notes: For 6 months in 191 men age 51 to 88 years with prostate cancer. Footnotes: * = Differences in incidences between groups were statistically significant. a = Due to unknown causes. Sources: [1][2][3] | ||||
Template documentationReferences
- ^ Jacobi GH (June 1982). "Intramuscular cyproterone acetate treatment for advanced prostatic carcinoma: results of the first multicentric randomized trial". In Schröder FH (ed.). Proceedings Androgens and Anti-androgens, International Symposium, Utrecht, June 5th, 1982. Schering Nederland BV. pp. 161–169. ISBN 978-9090004327. OCLC 11786945.
- ^ Jacobi GR, Tunn UW, Senge TH (1 December 1982). "Clinical experience with cyproterone acetate for palliation of inoperable prostate cancer". In Jacobi GH, Hohenfellner R (eds.). Prostate Cancer. Williams & Wilkins. pp. 305–319. ISBN 978-0-683-04354-9.
- ^ Namer M (October 1988). "Clinical applications of antiandrogens". Journal of Steroid Biochemistry. 31 (4B): 719–729. doi:10.1016/0022-4731(88)90023-4. PMID 2462132.